Showing results (11-20 of 90) with videos related to

Sort By:
Pageof 9
Plos One|June 10, 2014
Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteriaAndreas Clemens, Herbert Noack, Martina Brueckmann, et al.
Thrombosis and Haemostasis|December 22, 2011
Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilateSebastian Härtter, Norio Yamamura, Joachim Stangier, et al.
Thrombosis and Haemostasis|October 16, 2015
Dabigatran treatment simulation in patients undergoing maintenance haemodialysisKarl-Heinz Liesenfeld, Andreas Clemens, Joerg Kreuzer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 17, 2015
Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trialsShannon Cope, Andreas Clemens, Florence Hammès, et al.
Thrombosis Journal|January 2, 2013
Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant managementBastian Hass, Jayne Pooley, Adrian E Harrington, et al.
Contemporary Clinical Trials|March 25, 2019
Dose-response analysis of ranibizumab as-needed regimens for visual improvement in patients with diabetic macular edema using a modelling approachYuan Xiong, Etienne Pigeolet, Zufar Mulyukov, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|November 19, 2021
Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real-world studyTunde Peto, Toks Akerele, Alexandros Sagkriotis, et al.
Clinical Drug Investigation|March 23, 2013
Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjectsArne Ring, Karin Rathgen, Joachim Stangier, et al.
Contemporary Clinical Trials|March 22, 2021
Application of machine learning methods to bridge the gap between non-interventional studies and randomized controlled trials in ophthalmic patients with neovascular age-related macular degenerationAlexandros Sagkriotis, Usha Chakravarthy, Ray Griner, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 26, 2018
Neovascular Age-Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment EffectZufar Mulyukov, Sebastian Weber, Etienne Pigeolet, et al.
Pageof 9